Staffan is one of the founders of AroCell and has been active as an independent researcher since 1981. He has made a decisive contribution to the development of the company since it was founded in 2003. Staffan has devoted a large part of his research to studies of Thymidine kinase and its use as a biomarker in cancer and has published 29 publications and holds four approved patent families in many countries and two ongoing patent applications in the field.

“AroCell has developed very positively in recent years and as the company is now entering a commercial phase, it is the right time for me to leave the operational work. However, I look forward with great pleasure to following and supporting the company through my work in AroCell's Advisory Board", says Staffan Eriksson.

“It has been a privilege and a pleasure to have had the opportunity to work with Staffan and take part in his deep knowledge of TK1 and its use as a biomarker. However, Staffan does not leave the company but remains on our Advisory Board where he will continue to contribute with his experience and extensive knowledge", says Anders Hultman, CEO of AroCell.